Introduction {#sec1}
============

Giant cell tumor of bone (GCT) is a rare neoplasm. The entity was first described by Jaffe in 1940.[@bib1] The peak incidence is in the third and the fourth decades of life.[@bib2], [@bib3], [@bib4] Clinically it is usually seen as a lytic lesion of the epiphyseal region of bone. It most often occurs in the distal femur and proximal tibia. Radiologically usually a well-circumscribed lytic lesion over the epiphyseal region is found. Histopathologically, these tumors are comprised of mononuclear cells, macrophages and uniformly distributed multinuclear giant cells.[@bib3], [@bib5], [@bib6] GCT is regarded as a predominantly osteoclastogenic stromal tumor. It has been shown that the giant cells in GCT were reactive osteoclasts.[@bib7], [@bib8], [@bib9] The mononuclear stromal cells were claimed to be the neoplastic and proliferative component of GCT\'s and it has been reported that these neoplastic stromal cells had been capable of inducing osteoclast-like differentiation.[@bib6], [@bib10], [@bib11] Mononuclear monocytes were thought to be the osteoclast precursor cells.[@bib12], [@bib13] Mononuclear stromal cells may show rare mitotic figures, however atypical mitosis is absent.[@bib9] Mitotic figures are not seen in the multinucleated giant cells.[@bib3], [@bib6] Marked cytologic atypia is not present in mononuclear stromal cells.[@bib3], [@bib9]

They frequently display secondary changes complicating characteristic histopathological appearance. We evaluated our GCT cases diagnosed within 20 years period in a single institute retrospectively and discussed the histopathological findings.

Materials and methods {#sec2}
=====================

Archival material of the cases diagnosed as \"Giant cell tumor of bone\" between the years 1996--2016 were retrieved and included in this retrospective analysis. Cases were evaluated according to radiological features, clinical features such as age, gender, localization, recurrence, metastasis and histopathological features including accompanying fibrohistiocytic or aneurysmal bone cyst like components.

Results {#sec3}
=======

The case series included 120 patients, 64 female (53,3%) and 56 male (46,7%). Age range was between 12 and 80 ([Table 1](#tbl1){ref-type="table"}) with a mean age of 36.2 years. Tumors were localized most frequently at tibia (all 28 cases at the proximal part) and femur (21 of 25 cases at the distal part). In [Table 2](#tbl2){ref-type="table"}, localizations of the tumors are shown.Table 1Age distribution according to gender.Table 1Table 2Localization.Table 2

Radiological findings of 62 patients were available. Radiological consultation was done for these cases. A characteristic plain roentgenogram of GCT located at proximal metaphysis of tibia was shown in [Fig. 1](#fig1){ref-type="fig"}.Fig. 1Plain roentgenogram of a well defined lucent lesion of proximal tibia.Fig. 1

In 11 cases, areas rich in fibrohistiocytic component were detected (9,2% of the cases) ([Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}). In six of these tumors, this component was essentially fibroxanthomatous ([Fig. 4](#fig4){ref-type="fig"}). In 20 cases secondary aneurysmal bone cyst like component were observed (16,7% of the cases) ([Fig. 5](#fig5){ref-type="fig"}). In 2 cases both components were present. In all these cases, with additional sampling (2 samples for every 1 cm of the maximum diameter of the tumor, instead of 1 sample per 1 cm), characteristic areas consisting of mononuclear stromal cells and a second population of mononuclear monocytes and multinucleated giant cells, representing GCT were detected[@bib2] ([Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"}).Fig. 2Areas rich in fibrohistiocytic component (H-E, x100).Fig. 2Fig. 3Areas rich in fibrohistiocytic component (H-E, x100).Fig. 3Fig. 4Fibroxanthomatous areas (H-E, x100).Fig. 4Fig. 5Secondary aneurysmal bone cyst like areas (H-E, x40).Fig. 5Fig. 6Mononuclear cells and multinucleated giant cells (H-E, x100).Fig. 6Fig. 7Mononuclear cells and multinucleated giant cells (H-E, x200).Fig. 7

Coagulation necrosis were observed in 6 of the 23 recurrent cases (26%) and 10 of the remaining 97 cases (10,3%). One of these cases, displaying extensive necrosis, had been diagnosed as giant cell rich osteosarcoma in another pathology institute. Tumor had brisk mitotic activity and slight cytologic atypia adjacent to necrotic areas ([Fig. 8](#fig8){ref-type="fig"}), however atypical mitosis and malignant osteoid formation could not be detected.Fig. 8Slight cytologic atypia adjacent to necrotic areas (arrows) (H-E, x200).Fig. 8

Twenty three cases recurred (19,2% of the cases). Recurrence interval for 17 cases was known. Fourteen of these 17 cases showed recurrence within 3 years and 2 cases after 4 years. In one of our cases, the tumor, which was located at proximal tibia, showed recurrence 16 years later. Six cases showed multiple recurrences (2 or 3 occurrence). Sacrum was the most frequent site showing recurrence. Five of the 23 recurrent cases were located at sacrum (21,7%).

Metastasis to lung, 4 years after the primary diagnosis was detected in one case. Tumor was primarily located at calcaneus. During follow-up, tumor showed recurrence 3 times in 8 year-period following metastasis. Three months later following excision of the multiple metastases, new pulmonary metastatic nodules were detected and they were excised also.

The treatment modalities of 20 of 23 recurrent cases and of 48 of the nonrecurrent 97 cases were known. In recurrent cases, curettage and cementing for 14 patients, resection for 4 patients, firstly curettage and then resection in recurrence for 2 patients were performed. For 1 patient radiotherapy, for 4 patients RANKL inhibitor (Denosumab) and for 1 patient chemotherapy were used. In 1 patient endoprosthetic replacement were used for her recurrent tumor and since this replacement tumor did not recur. Twenty eight cases of nonrecurrent 48 cases were treated by curettage and cementing, 18 cases by resection, 2 cases by firstly curettage and then resection in recurrence. For 1 patient radiotherapy and for 2 patients RANKL inhibitor (Denosumab) were used.

Discussion {#sec4}
==========

GCT is a locally aggressive neoplasm with an unpredictable course. Although it has been reported that the occurrence of GCT in patients younger than 20 years and older than 55 years was unusual,[@bib3] in our case series 8 patients were younger than 20 (6,7% of the cases) and 13 patients were older than 55 (10,8% of the cases) (These incidences are consistent with the literature).[@bib14], [@bib15]

Nonepiphyseal GCT has been reported to be extremely rare.[@bib3] In our series we have observed 1 case at metaphysis.

The most common involved site was reported to be the distal end of the femur and the second was the proximal end of the tibia.[@bib2], [@bib3], [@bib4], [@bib5] In our case series, proximal tibia was the most frequent site for the tumor and the second most common site was distal femur.

It has been claimed that approximately 3--4% of GCT cases had been localized at small bones of hands and feet. In our series in 3 patients tumor was located at feet bones and 2 cases in hand (Total 5/120; 4,2%). GCT of small bones may be confused with giant cell reparative granuloma. Histopathologically, in giant cell reparative granuloma, mononuclear stromal cells are absent. It has been suggested that GCT of these bones had shown higher recurrence rate than the one in the long tubular bones.[@bib2] In 3 of our cases located at foot bones showed recurrence supporting this observation. A tumor of calcaneus bone, in addition to recurrences, displayed pulmonary metastases also.

The well defined histopathologic pattern of GCT is frequently lost by secondary reactive changes such as fibrohistiocytic proliferation, hemorrhage, necrosis and aneurysmal bone cyst formation. Fibrohistiocytic reaction sometimes become prominent and therefore in such cases differential diagnosis between nonossifying fibroma (NOF) and benign fibrous histiocytoma should be made. NOF occurs in metaphysis. Stroma is more fibroblastic in NOF than that of GCT, sometimes forming storiform pattern, and giant cells are more irregularly scattered in NOF. It has been observed that at the end stage of reparative processes following hemorrhage and necrosis; lipoidization, scarring and fibrohistiocytic proliferation had been formed.[@bib1], [@bib16] Benign fibrous histiocytomas do not contain broad sheets of mononuclear cells.[@bib17] In our case series we observed areas rich in fibrohistiocytic component in 11 cases. In six of these tumors, fibroxanthomatous pattern was dominant. In all cases characteristic areas representing GCT were found. We could not detect any adverse effect of these histopathological features on clinical outcome.

Aneurysmal bone cyst-like areas are frequently detected in GCT. Especially solid areas in aneurismal bone cyst may be misdiagnosed as GCT. In ABC, giant cells are smaller and giant cells are unevenly distributed. In solid type of ABC, stroma is more fibrotic than that of GCT.[@bib17] With additional sampling in all cases, areas showing typical GCT were detected except for 1 case. In this case, tumor presented with typical solid type ABC areas and the definitive diagnosis could not be made, GCT could not be excluded. Five months later tumor recurred and this time it displayed typical GCT areas with secondary ABC-like areas.

Necrosis with or without hemorrhage can be observed occasionally in conventional GCT. Adjacent to the necrotic areas, mononuclear stromal cells may show cytologic atypia focally, mimicking malignancy.[@bib2] However no atypical mitosis is present, supporting the benign nature of these changes. In our case series, although 16 cases showed necrosis, in no case marked cytologic atypia or atypical mitosis were present. Giant-cell rich osteosarcoma is a tumor that should be differentiated from GCT. In giant-cell rich osteosarcoma, nuclear pleomorphism, abnormal mitotic figures and malignant osteoid formation is characteristic. For only one case -- 28 year-old male patient -- which was located at metaphysis of fibula, evaluated in our institute within this 20 year-period, showing these histopathological findings, a diagnosis of 'osteosarcoma rich in giant cells' was given. This tumor showed soft tissue invasion also. A case which had been sent to our institute for consultation with a diagnosis of giant cell rich osteosarcoma, was revised and the diagnosis was changed as GCT, because no atypical mitosis or malignant osteoid formation had been detected.

Malignant GCT is a rarely observed entity. Related with differential diagnosis, it was reported that in primary malignant GCT, the tumor gradually progressed into the sarcomatous area.[@bib18] Although Bertoni et al had reported that in secondary malignant GCT, no residual conventional GCT had been found, Gong et al had observed in 4 of their 11 cases.[@bib18], [@bib19] We have not detected malignant transformation in any of our GCT cases.

Up to 50% of GCTs shows recurrence after curettage within 3 years.[@bib1]^,^[@bib3]^,^[@bib20] Rarely recurrence may occur after more than 3 years. In our series, one tumor showed recurrence 16 years later. Six cases showed multiple recurrences. Interestingly, sacrum was the site displaying recurrence most frequently (5 of the 23 recurrent cases -- 21,7%). Wide surgical excision was reported to reduce recurrence rate.[@bib1] In our case series recurrence was seen in 19,2% of patients.

Pulmonary metastases are reported to occur in approximately 1--2% of GCT patients.[@bib3] These nodules are amenable to surgical excision and they have a relatively good prognosis, however sometimes pulmonary spread can lead to death of the patient.[@bib2] In our series we have observed only 1 patient with pulmonary metastases.

Multifocal GCT is reported to occur very rarely without preexisting Paget\'s disease.[@bib3] In our series we have seen this situation in one case. Primary tumor was located at distal femur. It showed recurrence at the same localization and 4 months later second recurrence was presented at distal tibia. Interestingly, at the same time with the second recurrence, a fibrohistiocytic focus was detected at talus bone. Hyperparathyroidism was not detected, therefore this fibrohistiocytic focus was thought to represent a burned out GCT.

Main treatment option in GCT is surgery (usually curettage and cementing) and complementary radiotherapy. RANKL inhibitors (denosumab) and biphosphonates are new agents generally used for unresectable or metastatic disease. In our series RANKL inhibitors (denosumab) was only used in 6 patients and 2 of these patients showed recurrence in spite of therapy.

Conclusions {#sec5}
===========

-Proximal tibia was the most frequent site for GCT.-Secondary changes such as fibrohistiocytic or aneurysmal bone cyst-like components and coagulation necrosis were frequently seen in conventional GCT.-For tumors having prominent fibrohistiocytic and aneurysmal bone cyst-like components, in order to detect characteristic areas representing GCT, additional sampling is essential.-Secondary histopathological changes do not appear to affect clinical outcome, however recognizing these patterns is important in differential diagnosis and correct diagnosis of GCT.-Sacrum and foot bones were the most frequent sites for recurrence.-Approximately one fifth of GCT cases show recurrence.
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